SABS - SAB Biotherapeutics, Inc.
3.52
-0.280 -7.955%
Share volume: 555,970
Last Updated: 04-24-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances:
0.22%
PREVIOUS CLOSE
CHG
CHG%
$3.80
-0.28
-0.07%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 03-31-2025 | 09-30-2025 | 12-31-2025 | |
|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q1 2025 | Q3 2025 | Q4 2025 | |
| Report Date | 05-20-2024 | 08-08-2024 | 11-06-2024 | 05-09-2025 | 11-13-2025 | 03-09-2026 | |
| Total revenue | 944.575 K | 263.137 K | 0.000 | 0.000 | 0.000 | 0.000 | |
| Cost of revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Gross profit | 944.575 K | 263.137 K | 0.000 | 0.000 | 0.000 | 0.000 | |
| -72.14% | -100.00% | nan% | nan% | nan% | |||
| Operating expenses | 12.335 M | 10.465 M | 11.309 M | 10.772 M | 12.679 M | 15.770 M | |
| Selling general and admin | 4.189 M | 3.643 M | 3.479 M | 3.115 M | 3.709 M | 5.042 M | |
| Research and development | 8.146 M | 6.822 M | 7.831 M | 7.657 M | 8.970 M | 10.728 M | |
| Total expenses | 12.335 M | 10.465 M | 11.309 M | 10.772 M | 12.679 M | 15.770 M | |
| -15.16% | 8.07% | -4.75% | 17.70% | 24.38% | |||
| Operating income | -11.391 M | -10.202 M | -11.309 M | -10.772 M | -12.679 M | -15.770 M | |
| Ebit | -11.391 M | -7.617 M | -10.549 M | -5.190 M | 44.834 M | -17.498 M | |
| Pretax income | -5.026 M | -7.335 M | -10.349 M | -5.197 M | 45.445 M | -16.861 M | |
| 45.96% | 41.09% | -49.79% | -974.49% | -137.10% | |||
| Income tax | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income basic | -5.026 M | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| 100.00% | |||||||
| Net income | -5.026 M | -7.335 M | -10.349 M | -5.197 M | 45.445 M | -16.861 M | |
| -45.96% | -41.09% | 49.79% | 974.49% | -137.10% |